Berenberg Bank Reiterates €59.00 Price Target for Stratec Biomedical AG (ETR:SBS)
Separately, Oddo Securities set a €58.00 ($68.24) price objective on shares of Stratec Biomedical AG and gave the company a neutral rating in a research report on Monday, July 24th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has an average rating of Hold and an average price target of €60.00 ($70.59).
Shares of Stratec Biomedical AG (ETR:SBS) traded down 0.51% during midday trading on Tuesday, hitting €50.66. 103 shares of the stock were exchanged. The firm has a 50-day moving average of €54.08 and a 200-day moving average of €54.42. The company has a market capitalization of €602.25 million and a P/E ratio of 31.29. Stratec Biomedical AG has a 1-year low of €41.45 and a 1-year high of €63.18.
Stratec Biomedical AG Company Profile
STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other Segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.
Receive News & Stock Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related stocks with our FREE daily email newsletter.